Review

Acute Kidney Injury in Cardiorenal Syndrome Type 1 Patients: A Systematic Review and Meta-Analysis

Wim Vandenberghe^a Sofie Gevaert^b John A. Kellum^{d, e} Sean M. Bagshaw^f
Harlinde Peperstraete^a Ingrid Herck^a Johan Decruyenaere^a Eric A.J. Hoste^{a, c, e}

Departments of ^aIntensive Care Medicine and ^bCardiology, Ghent University Hospital, Ghent University, Ghent, and ^cResearch Foundation-Flanders (FWO), Brussels, Belgium; ^dCentre for Critical Care Nephrology, University of Pittsburgh, and ^eThe Clinical Research, Investigation, and Systems Modelling of Acute Illness (CRISMA) Centre, Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pa., USA; ^fDivision of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta., Canada

Key Words

Cardiorenal syndrome · Type 1 · Acute kidney injury · Meta-analysis

Abstract

Background: We evaluated the epidemiology and outcome of acute kidney injury (AKI) in patients with cardiorenal syndrome type 1 (CRS-1) and its subgroups: acute heart failure (AHF), acute coronary syndrome (ACS) and after cardiac surgery (CS). **Summary:** We performed a systematic review and meta-analysis. CRS-1 was defined by AKI (based on RIFLE, AKIN and KDIGO), worsening renal failure (WRF) and renal replacement therapy (RRT). We investigated the three most common clinical causes of CRS-1: AHF, ACS and CS. Out of 332 potential papers, 64 were eligible – with AKI used in 41 studies, WRF in 25 and RRT in 20. The occurrence rate of CRS-1, defined by AKI, WRF and RRT, was 25.4, 22.4 and 2.6%, respectively. AHF patients had a higher occurrence rate of CRS-1 compared to ACS and CS patients (AKI: 47.4 vs. 14.9 vs. 22.1%), but RRT was evenly distributed among the types of acute cardiac disease. AKI was associated with an increased mortality rate (risk ratio = 5.14, 95% CI 3.81–6.94; 24 studies and 35,227 patients), a longer length of stay in the intensive care unit [LOS_{ICU}] (median duration = 1.37 days, 95% CI 0.41–2.33; 9 studies and 10,758 patients) and a longer LOS in hospital [LOS_{hosp}] (median duration = 3.94 days, 95% CI 1.74–6.15; 8 studies and 35,227 patients). Increasing AKI severity was associated with worse outcomes. The impact of CRS-1 defined by AKI on mortality was greatest in CS patients. RRT had an even greater impact compared to AKI (mortality risk ratio = 9.2, median duration of LOS_{ICU} = 10.6 days and that of LOS_{hosp} = 20.2 days). **Key Messages:** Of all included patients, almost one quarter developed AKI and approximately 3% needed RRT. AHF patients experienced the highest occurrence rate of AKI, but the impact on mortality was greatest in CS patients.

© 2015 S. Karger AG, Basel

Wim Vandenberghe, MD
ICU, University Hospital Ghent
Ghent University
BE–9000 Ghent (Belgium)
E-Mail WimVDB.Vandenberghe@Ugent.be

Introduction

Cardiorenal syndrome (CRS) is a pathophysiologic disorder of the heart and kidneys, whereby acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other organ. In 2008, Ronco et al. proposed five subtypes of CRS according to the temporal sequence of organ failure as well as the clinical context [1]. CRS type 1 or acute cardiorenal syndrome (CRS-1) is characterized by an acute cardiac disease leading to acute kidney injury (AKI). The most common aetiologies for an acute cardiac disease include acute decompensated heart failure (AHF), acute coronary syndrome (ACS) and cardiac surgery (CS) [2].

The number of studies in the medical literature on this topic is hampered by the fact that at least 37 different definitions for AKI are being used [3]. This obviously makes any comparison between different studies difficult. In recent years, interdisciplinary consensus groups have proposed standardized criteria to define and stage AKI. The RIFLE (risk, injury, failure, loss of kidney function and end-stage kidney disease) classification and its modifications by the Acute Kidney Injury Network (AKIN) and the Kidney Disease: Improving Global Outcomes (KDIGO) group have been developed for the purpose of accurately diagnosing and assessing the severity and progression of AKI [4–7]. An alternative terminology and definition used, especially in publications on AHF, is worsening renal function (WRF).

The objective of this systematic review was to analyse the occurrence rate and outcome of CRS-1 according to the different definitions used for AKI, and for the three most frequent occurring aetiologies of CRS-1: AHF, ACS and CS.

Methods

Study Design

This is a systematic review and meta-analysis on CRS-1. The study was designed and is reported according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist [8].

Eligibility Criteria

We included retrospective and prospective cohort studies on adult populations with AHF, ACS or CS, providing epidemiological data on the rate of AKI and mortality in the short and long term. Only papers in English, French or Dutch, published between 1960 till present, were included. Exclusion criteria were: studies on animals, studies including children, case reports, reviews, intervention studies evaluating a specific treatment and duplicate publications.

The primary outcome was mortality. Secondary outcomes that were collected were data on length of stay in the intensive care unit (LOS_{ICU}), in the hospital (LOS_{hosp}) and occurrence rate of renal replacement therapy (RRT).

Search Strategy

The first selection of the search was performed by one investigator (W.V.), under supervision of the principal investigator (E.A.J.H.), who is a content expert. The scientific search engine PubMed was used, and included the period January 1, 1960 till February 28, 2015. The bibliographies of relevant papers were also consulted to retrieve further papers. For the PubMed search, we used the high-performance search filters for AKI as described by Hildebrand et al. [9], combined with the following medical subject headings (MeSH) terms: ‘cardiorenal syndrome’, ‘acute heart failure’, ‘acute coronary syndrome’ or ‘cardiac surgery’ (see online suppl. appendix 1; for all online suppl. material, see www.karger.com/doi/10.1159/000442300). Citations of included papers were collected using Reference Manager12 (Thomson Reuters®).

Data Extraction and Statistical Analysis

We (W.V. and E.A.J.H.) collected basic study characteristics: first author, year of publication, study period, country, retrospectively or prospectively gathered data; and population characteristics: occurrence rate of AKI, definition of AKI, subgroups of CRS-1 (AHF, ACS and CS), inclusion and exclusion criteria of the

Fig. 1. Flow diagram of the study selection. AKI = AKI defined by the RIFLE, AKIN or KDIGO classifications; WRF = AKI defined as worsening of renal function; RRT = AKI defined as the use of renal replacement therapy.

study, LOS_{ICU} and LOS_{hosp} , use of RRT. The collected data were directly extracted to an excel database (Microsoft®). The subgroups of CRS-1 and the definition of AKI were used to define and analyse the subpopulations.

The statistical analysis was performed with the software program SPSS Statistics 22 (IBM Corporation and Others®). The meta-analysis was performed with the software package Review Manager (RevMan) version 5.1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011), using the Mantel-Haenszel test (risk ratio). Several subgroups of AKI were analysed. First, all AKI cases using the RIFLE consensus definition or its modifications (AKIN and KDIGO) were grouped as AKI. Second, all AKI cases defined by variations of WRF were grouped as WRF. The final AKI subgroup was AKI cases treated with RRT (grouped as RRT). The occurrence rate of AKI is reported by the different definitions of AKI. In addition, we report on mortality, LOS_{ICU} and LOS_{hosp} . A random effect model was used to combine the data. As a sensitivity analysis, we analysed the prospective studies separately. Heterogeneity was assessed using a forest plot and the I^2 statistic. Bias was assessed by the risk of bias tool that is available in RevMan 5. Finally, a funnel plot was constructed for the assessment of heterogeneity and publication bias.

Results

The systematic literature search yielded 332 potential studies (fig. 1). We excluded 268 studies: animal studies (15), reviews (42), no epidemiological data available (177), not about CRS-1 (23), no data about AKI or WRF (8) and studies evaluating a specific intervention (3). Finally, we included 64 papers ($n = 509,766$ patients), containing data on AKI in AHF patients (18 studies; 29,202 patients) [4, 10–26], ACS (15 studies; 282,113 patients) [13, 27–40] and CS (32 studies; 198,451 patients) [41–72] (table 1). One study contained information about AHF as well as ACS and is therefore used in both groups [13].

AKI was defined by 10 different definitions (online suppl. table 1). AKI was used in 41 studies, subdivided into the RIFLE consensus definition in 30 studies, AKIN in 15 and KDIGO in 7. WRF, with 6 variants, was used in 25 studies, and RRT was used in 20 studies. A prospective study design was used in 29 (45%) studies (AHF 10, 56%; ACS 6, 40%, and CS 13, 41%).

Table 1. Baseline characteristics of the studies on patients with AHF, ACS and CS

First author	Year of publication	Type of data collection	CRS subgroup	AKI definition	Participants, n	Mean age of patients ± SD, years	DM, %
AHF							
1 Smith [24]	2003	Prospective	AHF	WRF	412	72±11	NA
2 Cowie [12]	2006	Prospective	AHF	WRF	299	68.0±11.6	32.8
3 Logaert [18]	2008	Prospective	AHF	WRF	416	71±13	22.8
4 Metra [19]	2008	Prospective	AHF	WRF	318	68±11	29.0
5 Aronson [10]	2010	Prospective	AHF	WRF	467	63±15	49.5
6 Verdiani [25]	2010	Prospective	AHF	WRF	394	78±10	33
7 Breidthardt [11]	2011	Prospective	AHF	WRF	657	79 (71–85)	31.0
8 Metra [20]	2012	Prospective	AHF	WRF	594	69.1±10.8	35.0
9 Mielniczuk [21]	2012	Prospective	AHF	WRF	34	67±15	31
10 Roy [4]	2012	Prospective	AHF	KDIGO, RIFLE, AKIN, WRF	637	64.6±14.3	23.7
Total					4,228	Mean 70.0	32.0
1 Krumholz [16]	2000	Retrospective	AHF	WRF	1,681	80±8	38.3
2 Nohria [22]	2008	Retrospective	AHF	WRF	433	56±14	15.5
3 Hata [14]	2010	Retrospective	AHF	RIFLE	376	69±12	NA
4 Kociol [15]	2010	Retrospective	AHF	WRF	20,063	NA	38.9
5 Eren [13]	2012	Retrospective	AHF, ACS	AKIN	53 (AHF)	NA	NA
6 Zhou [26]	2012	Retrospective	AHF	RIFLE	738	63±16	36.6
7 Shirakabe [23]	2013	Retrospective	AHF	RIFLE	625	72±12	37.7
8 Li [17]	2014	Retrospective	AHF	KDIGO	1,005	68.5±15.0	32.7
Total					24,974	Mean 68.1	35.5
ACS							
1 Marenzi [36]	2010	Prospective	ACS	WRF	97	66±11	18.6
2 Bruetto [30]	2012	Prospective	ACS	RIFLE	828	65 (54–74)	25.7
3 Lazaros [35]	2012	Prospective	ACS	WRF	447	NA	26.4
4 Alfaleh [27]	2013	Prospective	ACS	WRF	3,583	61.0±14.6	55.1
5 Hsieh [32]	2013	Prospective	ACS	RIFLE	622	NA	32.2
6 Rodrigues [40]	2013	Prospective	ACS	KDIGO, RIFLE	1,050	65 (55–74)	24.9
Total					6,627	Mean 64.3	42.0
1 Goldberg [31]	2005	Retrospective	ACS	WRF	1,038	63±14	24.5
2 Jose [33]	2006	Retrospective	ACS	WRF	1,854	NA	21.3
3 Latchamsetty [34]	2007	Retrospective	ACS	WRF	1,417	63	29.0
4 Newsome [38]	2008	Retrospective	ACS	WRF	87,094	77±8	52.1
5 Parikh [39]	2008	Retrospective	ACS	WRF	147,007	47±9	30.9
6 Amin [28]	2010	Retrospective	ACS	WRF	2,098	65±13	28.8
7 Amin [29]	2012	Retrospective	ACS	WRF	31,532	68.6	35.2
8 Eren [13]	2012	Retrospective	ACS, AHF	AKIN	236 (ACS)	NA	NA
9 Marenzi [37]	2013	Retrospective	ACS	AKIN	3,210	71±16	21.0
Total					275,486	Mean 65.0	37.9
CS							
1 Heringlake [54]	2006	Prospective	CS	RIFLE	29,623	NA	NA
2 Kuitunen [57]	2006	Prospective	CS	RIFLE	808	NA	NA
3 Lassnigg [58]	2008	Prospective	CS	RIFLE, AKIN	7,241	63 (19–90)	18.9
4 Haase [52]	2009	Prospective	CS	RIFLE, AKIN	282	72±10	27.0
5 De Santo [47]	2010	Prospective	CS	RIFLE	1,424	62±13	NA
6 Straugh [70]	2010	Prospective	CS, TAVI	RIFLE	28	82 (71–88)	8
7 Ho [55]	2012	Prospective	CS	KDIGO	345	63±10	8.1
8 Delgado [73]	2013	Prospective	CS	RIFLE	2,940	64.5±11.6	8.2
9 Hansen [53]	2013	Prospective	CS	RIFLE	1,030	65.8 (79–75)	16.1

Table 1 (continued)

First author	Year of publication	Type of data collection	CRS subgroup	AKI definition	Participants, n	Mean age of patients ± SD, years	DM, %
10 Kallel [74]	2013	Prospective	CS	RIFLE	136	55±14	28.0
11 Sampaio [68]	2013	Prospective	CS	KDIGO,RIFLE,AKIN	321	62 (53–71)	30
12 Elmistekawy [48]	2014	prospective	CS	AKIN	3,869	NA	NA
13 Rydén [67]	2014	Prospective	CS	AKIN	27,929	67.1±9.1	23.0
Total					75,976	Mean 65.6	21.0
1 Dasta [46]	2008	Retrospective	CS	RIFLE	3,741	70±10	39.9
2 Aregger [41]	2009	retrospective	CS, TAVI	RIFLE	58	83±5	12.0
3 Benedetto [44]	2009	Retrospective	CS	AKIN	705	68 (59–73)	39.2
4 Machado [61]	2009	Retrospective	CS	AKIN	817	61±9	34.8
5 Argalious [42]	2010	Retrospective	CS	RIFLE	10,648	NA	17.6
6 Robert [66]	2010	Retrospective	CS	RIFLE, AKIN	24,747	66±11	31.9
7 Testani [71]	2010	Retrospective	CS	RIFLE	3,914	NA	36.2
8 Englberger [49]	2011	Retrospective	CS	RIFLE,AKIN	4,836	64.4±14.2	20
9 Mariscalco [63]	2011	Retrospective	CS	RIFLE	414	62.5±11.5	8.7
10 Schneider [69]	2012	Retrospective	CS	RIFLE	1,504	67.9	29.9
11 Tolpin [72]	2012	Retrospective	CS	RIFLE	3,914	NA	36.2
12 Bastin [43]	2013	Retrospective	CS	RIFLE,AKIN	1,881	66 (56–74)	NA
13 Dardashti [45]	2013	Retrospective	CS	RIFLE	5,742	67.3±9.7	22.1
14 Englberger [50]	2013	Retrospective	CS	RIFLE	951	67±13	20.4
15 Liotta [59]	2014	Retrospective	CS	WRF	25,665	67.0±9.2	24.0
16 Nina [65]	2013	Retrospective	CS	RIFLE, AKIN	169	63±9	NA
17 Engoren [51]	2014	Retrospective	CS	KDIGO	1,543	NA	NA
18 Machado [62]	2014	Retrospective	CS	KDIGO	2,804	59 (49–66)	23
19 Ng [64]	2014	Retrospective	CS	WRF	28,422	Mean 66	NA
Total					122,475	Mean 66.5	27.0

Values in parentheses are interquartile ranges. DM = Diabetes mellitus; NA = not available.

Table 2. Occurrence rate of AKI in CRS-1 patients

	All AKI, %	Studies/ Patients	AKI, %	Studies/ Patients	WRF, %	Studies/ Patients	RRT, %	Studies/ Patients
<i>CRS-1 subgroup</i>								
All CRS-1	24.4 (12.9–36.6)	64/509,766	25.4 (14.3–38.9)	40/153,744	22.4 (11.8–33.1)	24/356,022	2.6 (1.8–4.7)	23/71,313
AHF	35.3 (25.2–46.2)	18/29,202	47.4 (39.1–63.3)	6/3,434	30.4 (24.2–35.9)	12/25,768	4.3 (1.0–8.8)	4/1,525
ACS	12.7 (10.7–17.0)	15/282,113	14.9 (13.2–20.7)	5/5,946	12.0 (8.8–14.1)	10/276,167	1.7 (1.3–2.2)	2/3,446
CS	22.1 (13.5–32.9)	32/198,451	22.1 (13.7–32.9)	30/144,364	6.4 (6.4–6.4)	2/54,087	3.1 (1.9–4.5)	17/66,342

Data are presented as proportions and interquartile ranges. AKI = AKI defined by the RIFLE, AKIN or KDIGO classifications; WRF = AKI defined as worsening of renal function; RRT = AKI defined as the use of renal replacement therapy.

A risk of bias analysis showed a low risk for selection bias in 55% of the studies, and the funnel plot could not indicate publication bias (fig. 2).

The use of different definitions resulted in a wide range of reported rates of AKI in CRS-1 patients. Table 2 summarises the occurrence rates of AKI according to the definition used and the CRS-1 subgroup. The median occurrence rate of AKI defined by any definition was 24.4%. A comparison of the AKI definition groups in CRS-1 reveals that AKI and WRF have a similar occurrence rate (25.4 and 22.4%, $p = 0.478$).

Fig. 2. Reported mortality rates over time, grouped by the year of publication in CRS-1 patients, AHF, ACS and after CS.

The subgroup of CRS-1 patients who had AHF had a higher occurrence rate of AKI (35.3%) in comparison to those with ACS and CS (12.7 and 22.1%, $p < 0.001$ and $p = 0.09$). This trend is similar when AKI was defined by AKI or WRF. In contrast, RRT was evenly distributed among all CRS-1 subtypes ($p = 0.611$; table 2), with a median occurrence rate of 2.6%.

The sub-analyses of AKI stages for patients classified as AKI demonstrated that the majority of patients had less severe AKI (table 3). The analysis of the subgroups of CRS-1 showed a similar trend for AKI severity.

Outcomes of CRS-1 and Its Subgroups

CRS-1: Whole Cohort

Most papers reported data on mortality after an observation period of 28 days (33 studies; table 4). Although, only a few papers reports long-term follow-up data on mortality, these included large patient cohorts and are therefore still informative.

Table 3. Occurrence rate of AKI according to the 3 stages of AKI and subclasses of CRS-1

	Risk/stage 1, %	Studies/ patients	Injury/stage 2, %	Studies/ patients	Failure/stage 3, %	Studies/ patients
CRS-1	17.9 (9.1–24.0)	27/99,561	4.4 (3.5–6.9)	28/101,442	3.6 (1.9–5.3)	17/99,561
AHF	34.2 (27.6–39.6)	5/2,797	11.7 (10.4–18.6)	5/2,797	9.1 (5.7–9.3)	5/2,797
ACS	9.2 (8.2–9.6)	5/5,763	4.3 (3.7–4.5)	5/5,763	3.2 (1.0–3.8)	5/5,763
CS	17.9 (9.6–22.0)	19/93,858	4.4 (3.5–5.6)	19/93,858	3.5 (1.9–4.5)	19/93,858

Data are presented as proportions and interquartile ranges. AKI = AKI defined by the RIFLE, AKIN or KDIGO classifications.

Table 4. Outcomes of CRS-1 according to the definition of AKI

	Period	All definitions	Studies/ Patients	AKI	Studies/ Patients	WRF	Studies/ Patients	RRT	Studies/ Patients
Mortality	28 days	4.90 (3.68–6.52)	33/56,860	5.14 (3.81–6.94)	24/35,227	5.19 (2.78–9.70)	12/51,805	9.16 (2.71–30.98)	5/6,556
	1 year	2.08 (1.27–3.42)	9/13,723						
	≥5 years	1.90 (1.50–2.41)	3/31,108						
LOS _{ICU}	28 days	1.46 (0.52–2.39)	10/10,855	1.37 (0.41–2.33)	9/10,758	3.00(0.04–5.96)	1/97	10.63(3.51–17.74)	3/5,799
LOS _{hosp}	28 days	3.51 (1.78–5.24)	13/8,733	3.94 (1.74–6.15)	8/6,649	2.65 (0.75–4.54)	5/2,084	20.20 (12.17–28.23)	3/6,045

Data are presented as risk ratio (95% CI) for mortality and weighted mean difference (95% CI) for LOS. AKI = AKI defined by the RIFLE, AKIN or KDIGO classifications; WRF = AKI defined as worsening of renal function; RRT = AKI defined as the use of renal replacement therapy; CI = confidence interval.

CRS-1 is correlated with an approximately 5-times increased risk for mortality after 28 days – confirmed by AKI as well as WRF (table 4). The mortality risk in RRT patients is almost twice as high as that of AKI. The risk for mortality after initial hospital survival is 2 times higher 1 and 5 years after CRS-1.

CRS-1 is associated with an increased LOS_{ICU} and LOS_{hosp} (1.5 and 3.5 days, respectively). When CRS-1 was defined by RRT, LOS_{ICU} and LOS_{hosp} dramatically increased by 11 and 20 days.

A higher severity stage of AKI is associated with a stepwise worsening of all outcomes (table 5). The outcome of CRS-1 also varies according to the underlying clinical condition. Table 6 illustrates the different outcomes in the CRS-1 subtypes, subdivided according to the definition of AKI.

A correlation analysis of mortality over time, grouped by the year of publication, indicate no significant change in CRS-1 (correlation coefficient –0.07, *p* 0.68) and its subgroups AHF, ACS and CS (correlation coefficient: –0.05, *p* = 0.88; –0.80, *p* = 0.10; –0.32, *p* = 0.20, respectively; fig. 2).

Acute Heart Failure

We observed a significant increased mortality (risk ratio 2.89), but the impact was less in this cohort compared to ACS and CS patients. When defined as WRF, CRS-1 was associated with a longer LOS_{ICU}. LOS_{hosp} was increased for CRS-1 defined by WRF and AKI defined by the KDIGO classification. We found no studies that reported on CRS-1 defined as RRT in this cohort.

Acute Coronary Syndrome

We found important differences in the mortality rate associated with CRS-1 in ACS patients. CRS-1 defined by AKI was associated with a 3.5-times increased risk for mortality, while WRF was associated with a 17-times increased risk. This may be explained by the differences in

Table 5. Outcomes of CRS-1 according to the severity of AKI when defined as AKI

	Risk/stage1	Studies/ Patients	Injury/stage2	Studies/ Patients	Loss/stage 3	Studies/ Patients
Mortality	3.45 (2.25–5.31)	16/53,066	9.57 (6.31–14.50)	13/39,644	20.37 (13.19–31.48)	12/38,575
LOS _{ICU}	0.99 (0.65–1.33)	8/16,348	2.22 (0.89–3.55)	7/12,479	8.32(3.39–13.24)	7/12,479
LOS _{hosp}	3.51 (2.63–4.39)	10/17,713	8.32 (5.87–10.78)	9/13,844	18.41 (14.74–22.09)	9/13,844

Data are presented as risk ratio (95% CI) for mortality and weighted mean difference (95% CI) for LOS. AKI = AKI defined by the RIFLE, AKIN or KDIGO classifications; WRF = AKI defined as worsening of renal function; RRT = AKI defined as the use of renal replacement therapy; CI = confidence interval.

Table 6. Mortality, LOS_{ICU} and LOS_{hosp} in the subtypes of CRS-1 according to the definition of AKI

Outcome	Sub-group	AKI	Studies/ Patients	WRF	Studies/ Patients	RRT	Studies/ Patients
Mortality	AHF	2.89 (2.14–3.89)	5/4,018	2.37 (1.65–3.38)	8/5,050		
	ACS	3.53 (2.04–6.10)	3/5,088	16.95 (12.00–23.93)	2/4,621	2.72 (1.52–4.88)	1/97
	CS	7.51 (5.58–10.11)	16/26,121	17.11 (9.53–30.73)	2/42,134	7.55 (1.28–44.39)	4/5,605
LOS _{ICU}	AHF	0.35 (–0.80–1.51)	3/2,119	3.00 (0.04–5.96)	1/97		
	ACS	2.00 (1.88–2.12)	1/3,210				
	CS	1.68 (0.38–2.97)	5/5,429			10.63 (3.51–17.74)	3/5,799
LOS _{hosp}	AHF	5.79 (1.21–10.37)	4/2,172	2.65 (0.75–4.54)	5/2,084		
	ACS	2.08 (1.01–3.15)	1/236				
	CS	3.56 (–1.05–8.16)	4/4,241			20.20 (12.17–28.23)	3/6,045

Data are presented as risk ratio (95% CI) for mortality and weighted mean difference (95% CI) for LOS. AKI = AKI defined by the RIFLE, AKIN or KDIGO classifications; WRF = AKI defined as worsening of renal function; RRT = AKI defined as the use of renal replacement therapy; CI = confidence interval.

definition and the variant of WRF used, but probably more importantly also the differences in baseline characteristics of the patients. The association of RRT and mortality was only reported in 1 study (including 97 patients), limiting the strength of the observed risk ratio. CRS-1 defined by AKI was associated with a 2 days longer LOS in the ICU as well in the hospital.

Cardiac Surgery

CS patients who had CRS-1 had the highest mortality risk of all 3 subtypes of CRS-1. The 2 studies that reported on WRF revealed a 17-times increased risk for mortality. Similar to AHF patients, the most obvious explanation for this important difference may be the differences in baseline characteristics between the study cohorts. LOS was only moderately increased in the ICU, and remarkably, LOS_{hosp} was similar to CS patients without CRS-1.

Discussion

A total of 64 studies, including 509,766 patients, were analysed in this systematic review on the epidemiology of CRS-1. We found that 10 different definitions for AKI were used in these publications. These could be grouped in AKI, WRF and RRT. AKI and WRF occurred in

approximately one-fifth of the patients with acute cardiac disease, and they were associated with a 5-times increased risk for death and a 1–4 days longer LOS. RRT occurred in 2.6% of the patients with acute cardiac disease, and it was associated with a 9-times increased risk for death. These patients had a 10 and 20 days longer LOS in the ICU and hospital, respectively.

We found important differences between the occurrence rate of CRS-1 and outcomes in the 3 subgroups of acute cardiac disease. AHF patients experienced the highest rates of AKI (defined by the KDIGO guidelines) and WRF, but the rate of RRT was similar among the 3 different acute cardiac diseases. CRS-1, defined by any definition, had the greatest impact on mortality in CS patients.

There may be several explanations for the higher occurrence of CRS-1 in AHF patients. First, heart failure patients do more likely have decreased renal perfusion as a consequence of forward and/or backward failure. This is less frequently occurring in patients who develop CRS-1 as a consequence of ACS or CS. Second, a considerable number of patients who had AHF may also have suffered from chronic heart failure, a condition associated with chronic impairment of kidney function. Third, the therapy for AHF includes potential nephrotoxic drugs, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Finally, unmeasured differences in the baseline characteristics of the AHF patients may also explain the higher occurrence rate of CRS-1.

Although, the occurrence rate of AKI is highest in AHF patients, the impact of AKI on mortality is more pronounced in patients who underwent CS. Several explanations are possible. First, AKI could be a surrogate marker of severe complications after CS, for example peri-operative blood loss, AHF, ACS, stunning of the heart due to multiple episodes or a prolonged period on cardiopulmonary bypass, post-operative infections or thrombo-embolic processes. All these events can result in an additional deterioration of kidney function, and some of these have an important impact on outcome. Second, the higher severity of AKI in the CS group may explain the worse outcome. We found that RRT occurred more frequently in CS patients. On the other hand, AKI stage 3 was less frequent, although peri-operative fluid loading, resulting in a dilution of serum creatinine and false low AKI staging, could bias this.

Study Strengths and Limitations

This review includes over 60 studies with more than half a million patients and presents a comprehensive overview of all studies reporting on AKI in patients with CRS-1, defined according to the different definitions of AKI used, including the newest KDIGO variant. In addition, we evaluated in a sub-analysis, the 3 most important categories of acute cardiac disease leading to CRS-1. Although we searched for studies published between 1960 till present, we could only include studies published since 2000. This guarantees that the data presented in this study are contemporary and valid for present-day practice.

We would like to mention several limitations. First, we did not include studies on AKI caused by contrast agents during coronary interventions, because in these patients, AKI is a toxic reaction secondary to contrast exposure, rather than a consequence of acute cardiac disease. Second, studies have used different durations of observation time for the ascertainment of AKI. These variations in ascertainment for AKI have the potential to introduce bias and misclassification. The most common definition for AKI has been at any time during hospital admission. Third, despite of grouping the AKI definitions, there is still considerable heterogeneity within each group. We found 6 variants of WRF, and AKI was also defined according to the different modifications of the original RIFLE classification – AKIN and KDIGO. Additionally, the indications and exclusion criteria for RRT are diverse, resulting in a heterogeneous cohort. Fourth, none of the studies used the urine output criteria for AKI. Fifth, bias and heterogeneity may limit this systematic review. To assess the quality of the collected

papers, we performed a risk of bias analysis. This showed a low risk for selection bias in only 55% of the papers and prospective data collection in 45%. The I^2 statistic of 87% (fig. 1) also indicates an important statistical heterogeneity among the studies. Finally, the 5-year mortality rate was based on only 3 studies, limiting the strength of this observation.

Conclusions

Almost one quarter of the patients included had AKI, and RRT was used in approximately 3%. AKI was associated with significantly worse outcomes. AHF patients experienced the highest occurrence rate of AKI, but the impact on mortality was greatest in CS patients.

Disclosure Statement

S.M.B. reports consulting and speaking fees for Baxter Healthcare Corp. J.D. reports grants from Fresenius, from GE Healthcare, from Ferring and from MSD outside the submitted work. E.A.J.H. reports personal fees from Astute Medical and grants from Industrial Research Fund, Ghent University outside the submitted work. All other authors declare no conflicts of interest.

References

- 1 Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. *J Am Coll Cardiol* 2008;52:1527–1539.
- 2 Bagshaw SM, Cruz DN: Epidemiology of cardiorenal syndromes. *Contrib Nephrol* 2010;165:68–82.
- 3 Hoste EA, Cruz DN, Davenport A, Mehta RL, Piccinni P, Tetta C, Viscovo G, Ronco C: The epidemiology of cardiac surgery-associated acute kidney injury. *Int J Artif Organs* 2008;31:158–165.
- 4 Roy AK, Mc Gorrigan C, Treacy C, Kavanaugh E, Brennan A, Mahon NG, Murray PT: A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. *Cardiorenal Med* 2013;3:26–37.
- 5 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. *Kidney Int* 2012;2:1–138.
- 6 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204–R212.
- 7 Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11:R31.
- 8 Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- 9 Hildebrand AM, Iansavichus AV, Haynes RB, Wilczynski NL, Mehta RL, Parikh CR, Garg AX: High-performance information search filters for acute kidney injury content in PubMed, Ovid Medline and Embase. *Nephrol Dial Transplant* 2014;29:823–832.
- 10 Aronson D, Burger AJ: The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. *J Card Fail* 2010;16:541–547.
- 11 Breidthardt T, Socrates T, Noveanu M, Klima T, Heinisch C, Reichlin T, Potocki M, Nowak A, Tschung C, Arenja N, Bingisser R, Mueller C: Effect and clinical prediction of worsening renal function in acute decompensated heart failure. *Am J Cardiol* 2011;107:730–735.
- 12 Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B: Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). *Eur Heart J* 2006;27:1216–1222.
- 13 Eren Z, Ozveren O, Buvukoner E, Kaspar E, Degertekin M, Kantarci G: A single-centre study of acute cardiorenal syndrome: incidence, risk factors and consequences. *Cardiorenal Med* 2012;2:168–176.
- 14 Hata N, Yokoyama S, Shinada T, Kobayashi N, Shirakabe A, Tomita K, Kitamura M, Kurihara O, Takahashi Y: Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. *Eur J Heart Fail* 2010;12:32–37.
- 15 Kociol RD, Greiner MA, Hammill BG, Phatak H, Fonarow GC, Curtis LH, Hernandez AF: Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure. *Am J Cardiol* 2010;105:1786–1793.

- 16 Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RJ: Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. *Am J Cardiol* 2000; 85:1110–1113.
- 17 Li Z, Cai L, Liang X, Du Z, Chen Y, An S, Tan N, Xu L, Li R, Li L, Shi W: Identification and predicting short-term prognosis of early cardiorenal syndrome type 1: KDIGO is superior to RIFLE or AKIN. *PLoS One* 2014;9: e114369.
- 18 Logeart D, Tabet JY, Hittinger L, Thabut G, Jourdain P, Maison P, Tartiere JM, Solal AC: Transient worsening of renal function during hospitalization for acute heart failure alters outcome. *Int J Cardiol* 2008;127:228–232.
- 19 Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei CL: Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. *Eur J Heart Fail* 2008;10:188–195.
- 20 Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei CL: Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. *Circ Heart Fail* 2012;5:54–62.
- 21 Mielniczuk LM, Chandy G, Stewart D, Contreras-Dominguez V, Haddad H, Pugliese C, Davies RA: Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. *Congest Heart Fail* 2012;18:151–157.
- 22 Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA: Cardiorenal interactions: insights from the ESCAPE trial. *J Am Coll Cardiol* 2008;51:1268–1274.
- 23 Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H, Yamamoto Y, Yokoyama S, Asai K, Mizuno K: Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. *Circ J* 2013;77:687–696.
- 24 Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? *J Card Fail* 2003;9:13–25.
- 25 Verdiani V, Lastrucci V, Nozzoli C: Worsening renal function in patients hospitalized with acute heart failure: risk factors and prognostic significances. *Int J Nephrol* 2010;2011:785974.
- 26 Zhou Q, Zhao C, Xie D, Xu D, Bin J, Chen P, Liang M, Zhang X, Hou F: Acute and acute-on-chronic kidney injury of patients with decompensated heart failure: impact on outcomes. *BMC Nephrol* 2012;13:51.
- 27 Alfaleh HF, Alsuwaida AO, Ullah A, Hersi A, Alhabib KF, Alnemer K, Alsaif S, Taraben A, Kashour T, Balghith MA, Ahmed WH: The prognostic impact of in-hospital worsening of renal function in patients with acute coronary syndrome. *Int J Cardiol* 2013;167:866–870.
- 28 Amin AP, Spertus JA, Reid KJ, Lan X, Buchanan DM, Decker C, Masoudi FA: The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. *Am Heart J* 2010;160: 1065–1071.
- 29 Amin AP, Salisbury AC, McCullough PA, Gosch K, Spertus JA, Venkitachalam L, Stolker JM, Parikh CR, Masoudi FA, Jones PG, Kosiborod M: Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. *Arch Intern Med* 2012;172:246–253.
- 30 Bruetto RG, Rodrigues FB, Torres US, Otaviano AP, Zanetta DM, Burdmann EA: Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction. *PLoS One* 2012;7:e35496.
- 31 Goldberg A, Hammerman H, Petcherski S, Zdoroviyak A, Yalonetsky S, Kapeliovich M, Agmon Y, Markiewicz W, Aronson D: In-hospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. *Am Heart J* 2005;150:330–337.
- 32 Hsieh MJ, Chen YC, Chen CC, Wang CL, Wu LS, Wang CC: Renal dysfunction on admission, worsening renal function, and severity of acute kidney injury predict 2-year mortality in patients with acute myocardial infarction. *Circ J* 2013;77:217–223.
- 33 Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moya L, Pfeffer MA, Solomon SD: Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. *J Am Soc Nephrol* 2006;17:2886–2891.
- 34 Latchamsetty R, Fang J, Kline-Rogers E, Mukherjee D, Otten RF, LaBounty TM, Emery MS, Eagle KA, Froehlich JB: Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. *Am J Cardiol* 2007;99:939–942.
- 35 Lazaros G, Tsiachris D, Tousoulis D, Patialiakas A, Dimitriadis K, Roussos D, Vergopoulos E, Tsioufis C, Vlachopoulos C, Stefanadis C: In-hospital worsening renal function is an independent predictor of one-year mortality in patients with acute myocardial infarction. *Int J Cardiol* 2012;155:97–101.
- 36 Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, Moltrasio M, Rubino M, Veglia F, Montorsi P, Bartorelli AL: Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. *Crit Care Med* 2010;38:438–444.
- 37 Marenzi G, Cabiati A, Bertoli SV, Assanelli E, Marana I, De Metrio M, Rubino M, Moltrasio M, Grazi M, Campodonico J, Milazzo V, Veglia F, Lauri G, Bartorelli AL: Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. *Am J Cardiol* 2013;111:816–822.
- 38 Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, Allison JJ: Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. *Arch Intern Med* 2008;168:609–616.

- 39 Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM: Long-term prognosis of acute kidney injury after acute myocardial infarction. *Arch Intern Med* 2008;168:987–995.
- 40 Rodrigues FB, Bruetto RG, Torres US, Otaviano AP, Zanetta DM, Burdmann EA: Incidence and mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO and RIFLE criteria. *PLoS One* 2013;8:e69998.
- 41 Aregger F, Wenaweser P, Hellige GJ, Kadner A, Carrel T, Windecker S, Frey FJ: Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. *Nephrol Dial Transplant* 2009;24:2175–2179.
- 42 Argalious M, Xu M, Sun Z, Smedira N, Koch CG: Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery. *Anesth Analg* 2010;111:324–330.
- 43 Bastin AJ, Ostermann M, Slack AJ, Diller GP, Finney SJ, Evans TW: Acute kidney injury after cardiac surgery according to Risk/Injury/Failure/Loss/End-stage, Acute Kidney Injury Network, and Kidney Disease: Improving Global Outcomes classifications. *J Crit Care* 2013;28:389–396.
- 44 Benedetto U, Luciani R, Goracci M, Capuano F, Refice S, Angeloni E, Roscitano A, Sinatra R: Miniaturized cardiopulmonary bypass and acute kidney injury in coronary artery bypass graft surgery. *Ann Thorac Surg* 2009;88:529–535.
- 45 Dardashti A, Ederoth P, Algotsson L, Bronden B, Bjursten H: Incidence, dynamics, and prognostic value of acute kidney injury for death after cardiac surgery. *J Thorac Cardiovasc Surg* 2014;147:800–807.
- 46 Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA: Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. *Nephrol Dial Transplant* 2008;23:1970–1974.
- 47 De Santo LS, Romano G, Galdieri N, Buonocore M, Bancone C, De Simone V, Della Corte A, Nappi G: RIFLE criteria for acute kidney injury in valvular surgery. *J Heart Valve Dis* 2010;19:139–147.
- 48 Elmistekawy E, McDonald B, Hudson C, Ruel M, Mesana T, Chan V, Boodhwani M: Clinical impact of mild acute kidney injury after cardiac surgery. *Ann Thorac Surg* 2014;98:815–822.
- 49 Englberger L, Suri RM, Li Z, Casey ET, Daly RC, Dearani JA, Schaff HV: Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. *Crit Care* 2011;15:R16.
- 50 Englberger L, Suri RM, Connolly HM, Li Z, Abel MD, Greason KL, Dearani JA, Schaff HV: Increased risk of acute kidney injury in patients undergoing tricuspid valve surgery. *Eur J Cardiothorac Surg* 2013;43:993–999.
- 51 Engoren M, Habib RH, Arslanian-Engoren C, Kheterpal S, Schwann TA: The effect of acute kidney injury and discharge creatinine level on mortality following cardiac surgery*. *Crit Care Med* 2014;42:2069–2074.
- 52 Haase M, Bellomo R, Matalanis G, Calzavacca P, Dragun D, Haase-Fielitz A: A comparison of the RIFLE and Acute Kidney Injury Network classifications for cardiac surgery-associated acute kidney injury: a prospective cohort study. *J Thorac Cardiovasc Surg* 2009;138:1370–1376.
- 53 Hansen MK, Gammelager H, Mikkelsen MM, Hjortdal VE, Layton JB, Johnsen SP, Christiansen CF: Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study. *Crit Care* 2013;17:R292.
- 54 Heringlake M, Knappe M, Vargas HO, Luft H, Kindgen-Milles D, Bottiger BW, Weigand MR, Klaus S, Schirmer U: Renal dysfunction according to the ADQI-RIFLE system and clinical practice patterns after cardiac surgery in Germany. *Minerva Anesthesiol* 2006;72:645–654.
- 55 Ho J, Reslerova M, Gali B, Nickerson PW, Rush DN, Sood MM, Buetti J, Komenda P, Pascoe E, Arora RC, Rigatto C: Serum creatinine measurement immediately after cardiac surgery and prediction of acute kidney injury. *Am J Kidney Dis* 2012;59:196–201.
- 56 Kallel S, Triki Z, Abdenadher M, Frikha I, Jemel A, Karoui A: Acute renal failure after cardiac surgery: evaluation of the RIFLE criteria (in French). *Nephrol Ther* 2013;9:108–114.
- 57 Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettila V: Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. *Ann Thorac Surg* 2006;81:542–546.
- 58 Lassnigg A, Schmid ER, Hiesmayr M, Falk C, Druml W, Bauer P, Schmidlin D: Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? *Crit Care Med* 2008;36:1129–1137.
- 59 Liotta M, Olsson D, Sartipy U, Holzmann MJ: Minimal changes in postoperative creatinine values and early and late mortality and cardiovascular events after coronary artery bypass grafting. *Am J Cardiol* 2014;113:70–75.
- 60 Lopez-Delgado JC, Esteve F, Torrado H, Rodriguez-Castro D, Carrio ML, Farrero E, Javierre C, Ventura JL, Manez R: Influence of acute kidney injury on short- and long-term outcomes in patients undergoing cardiac surgery: risk factors and prognostic value of a modified RIFLE classification. *Crit Care* 2013;17:R293.
- 61 Machado MN, Miranda RC, Takakura IT, Palmegiani E, Santos CA, Oliveira MA, Mouco OM, Hernandez ME, Lemos MA, Maia LN: Acute kidney injury after on-pump coronary artery bypass graft surgery. *Arq Bras Cardiol* 2009;93:247–252.
- 62 Machado MN, Nakazone MA, Maia LN: Prognostic value of acute kidney injury after cardiac surgery according to kidney disease: improving global outcomes definition and staging (KDIGO) criteria. *PLoS One* 2014;9:e98028.
- 63 Mariscalco G, Nicolini F, Scannapieco A, Gherli R, Serraino F, Dominici C, Renzulli A, Gherli T, Sala A, Beghi C: Acute kidney injury after composite valve-graft replacement for ascending aorta aneurysms. *Heart Vessels* 2013;28:229–236.

- 64 Ng SY, Sanagou M, Wolfe R, Cochrane A, Smith JA, Reid CM: Prediction of acute kidney injury within 30 days of cardiac surgery. *J Thorac Cardiovasc Surg* 2014;147:1875–83, 1883.
- 65 Nina VJ, Matias MM, Brito DJ, de Figueiredo Neto JA, Coutinho LB, Rodrigues RF, Mendes VG, Gaspar SF: Acute kidney injury after coronary artery bypass grafting: assessment using RIFLE and AKIN criteria. *Rev Bras Cir Cardiovasc* 2013;28:231–237.
- 66 Robert AM, Kramer RS, Dacey LJ, Charlesworth DC, Leavitt BJ, Helm RE, Hernandez F, Sardella GL, Frumiento C, Likosky DS, Brown JR: Cardiac surgery-associated acute kidney injury: a comparison of two consensus criteria. *Ann Thorac Surg* 2010;90:1939–1943.
- 67 Ryden L, Ahnve S, Bell M, Hammar N, Ivert T, Sartipy U, Holzmann MJ: Acute kidney injury after coronary artery bypass grafting and long-term risk of myocardial infarction and death. *Int J Cardiol* 2014;172:190–195.
- 68 Sampaio MC, Maximo CA, Montenegro CM, Mota DM, Fernandes TR, Bianco AC, Amodeo C, Cordeiro AC: Comparison of diagnostic criteria for acute kidney injury in cardiac surgery. *Arq Bras Cardiol* 2013;101:18–25.
- 69 Schneider AG, Eastwood GM, Seevanayagam S, Matalanis G, Bellomo R: A risk, injury, failure, loss, and end-stage renal failure score-based trigger for renal replacement therapy and survival after cardiac surgery. *J Crit Care* 2012;27:488–495.
- 70 Strauch JT, Scherner MP, Haldenwang PL, Pfister R, Kuhn EW, Madershahian N, Rahmanian P, Wippermann J, Wahlers T: Minimally invasive transapical aortic valve implantation and the risk of acute kidney injury. *Ann Thorac Surg* 2010;89:465–470.
- 71 Testani JM, Khera AV, St John Sutton MG, Keane MG, Wiegers SE, Shannon RP, Kirkpatrick JN: Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. *Am J Cardiol* 2010;105:511–516.
- 72 Tolpin DA, Collard CD, Lee VV, Virani SS, Allison PM, Elayda MA, Pan W: Subclinical changes in serum creatinine and mortality after coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2012;143:682–688.